Enzychem Lifesciences Corp
Company Profile
Business description
Enzychem Lifesciences Corp develops and produces APIs and functional health foods. The company's business divisions are divided into the Global New Drug Development, Pharmaceutical Active Ingredients, and Health Functional Foods divisions, as well as the Bio-oil (HVO raw materials, SAF raw materials) business division of its subsidiary. The products of the company include erdosteine (cough suppressant/expectorant), gadobutrol (contrast agent), D-cycloserine (anti-tuberculosis agent), sarpogrelate (anticoagulant), zinc carnosine (anti-ulcer agent), and zaltoprofen (anti-inflammatory analgesic), and others.
Contact
59, Biovalley-ro
Wangam-dong
Jecheon-siChungcheongbuk-do135-280
KORT: +82 436522845
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
130
Stocks News & Analysis
stocks
ASX healthcare share remains undervalued ahead of earnings
stocks
Alphabet earnings: Strong AI monetization continues to spearhead results
stocks
AMD: We’re pleased with Anthropic Partnership ahead of advancing AI event
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,968.00 | 6.20 | -0.07% |
| CAC 40 | 8,299.09 | 138.80 | -1.64% |
| DAX 40 | 24,763.12 | 392.29 | -1.56% |
| Dow JONES (US) | 51,711.65 | 506.93 | -0.97% |
| FTSE 100 | 10,639.17 | 77.80 | -0.73% |
| HKSE | 25,210.81 | 318.15 | 1.28% |
| NASDAQ | 25,137.69 | 553.21 | -2.15% |
| Nikkei 225 | 64,787.62 | 1,634.98 | -2.46% |
| NZX 50 Index | 13,741.85 | 53.46 | -0.39% |
| S&P 500 | 7,408.30 | 90.66 | -1.21% |
| S&P/ASX 200 | 8,795.00 | 0.70 | -0.01% |
| SSE Composite Index | 3,876.21 | 0.57 | -0.01% |